Navigation Links
AnaptysBio Adds Dr. David L. Lacey and Dr. Michael Gallatin to Therapeutic Advisory Board
Date:3/15/2012

SAN DIEGO, March 15, 2012 /PRNewswire/ -- AnaptysBio, Inc., a privately held therapeutic antibody company, today announced the addition of David L. Lacey, M.D. and Michael Gallatin, Ph.D. to the company's Therapeutic Advisory Board (TAB).  Drs. Lacey and Gallatin will join two founding members of AnaptysBio's TAB, Jan de Vries, Ph.D. and Nicholas B. Lydon, Ph.D.

(Logo: http://photos.prnewswire.com/prnh/20111205/SF16052LOGO)

AnaptysBio's TAB is constituted to oversee the company's internal product pipeline, including the identification of antibody targets, selection of lead candidates for preclinical development and design of clinical development strategies.  AnaptysBio is currently advancing internal programs across a number of therapeutic areas, including autoimmunity/inflammation, cancer immunotherapy and muscle wasting disorders. 

"We are pleased to augment our TAB with the addition of Dr. Lacey and Dr. Gallatin's world-recognized expertise," said Hamza Suria, AnaptysBio's president and chief executive officer. "AnaptysBio will continue to expand its product pipeline with compelling therapeutic antibody candidates generated using our SHM-XEL platform."

Dr. Lacey is a former senior vice president and head of discovery research at Amgen with over 30 years of basic and clinical research experience.  Dr. Lacey played a fundamental role in the discovery of the OPG/RANKL/RANK pathway at Amgen as well as the development of the anti-RANKL human antibody known as denosumab.  He was most recently responsible for leading a group of over 1,200 FTEs in Amgen's discovery research unit across hundreds of preclinical projects in hematology/oncology, inflammation, metabolic disorders and neuroscience.  Dr. Lacey received an M.D. from the University of Colorado and was trained in pathology at the Washington University Medical Center, St. Louis, MO.  

Dr. Gallatin is a former vice president and scientific director of ICOS Corporation, where his responsibilities included discovery, preclinical research, medicinal chemistry and process chemistry groups, including those responsible for worldwide development and launch of tadalafil (Cialis®). Subsequently, Dr. Gallatin helped found Stromedix, which focused on novel treatments for chronic fibrotic diseases and was recently acquired by Biogen Idec.  Dr. Gallatin also co-founded and was president of Calistoga Pharmaceuticals, the first company to demonstrate clinical benefit of isoform-selective PI3 kinase inhibition, subsequently acquired by Gilead.  He has also been a member of the Scientific Advisory Boards of the Keystone Symposia, Caprion, and the University of Texas Department of Chemistry, a member of the BioSeek Board of Directors and has recently also joined the Board of Directors of the Benaroya Research Institute.  Dr. Gallatin received his Ph.D. from the University of Alberta's Department of Immunology, and discovered the first cell adhesion molecule implicated in site-selective leukocyte traffic while a Damon Runyon-Walter Winchell and American Cancer Society fellow at Stanford University in the laboratory of Dr. Irving Weissman. Dr. Gallatin is a former faculty member of the Fred Hutchinson Cancer Center and is currently a senior advisor to Frazier Healthcare.

Dr. de Vries is a former head of the Novartis Research Institutes for BioMedical Research in Basel, Switzerland. While at Novartis, Dr. de Vries led the early development of many drugs that are now on the market or in late-stage clinical development, including Elidel® for the treatment of atopic dermatitis, Ilaris® (canakinumab) for the treatment of various chronic inflammatory diseases and diabetes, Gilenia® for the treatment of multiple sclerosis and AIN-457, an IL-17 mAb for the treatment of autoimmune diseases. Dr. de Vries received his Ph.D. in Immunology from the University of Amsterdam and spent two years as a visiting scientist at the University of California, San Diego. 

Dr. Lydon is a co-founder of AnaptysBio and won the 2009 Lasker-DeBakey Clinical Medical Research Award along with two other scientists for the development of Gleevec® (imatinib), a molecularly-targeted treatment for chronic myeloid leukemia, which converted a fatal cancer into a manageable chronic condition.  Dr. Lydon holds a doctorate in biochemistry from University of Dundee, Scotland, and has previously served as vice president, small molecule drug discovery at Amgen, Inc.  Prior to joining Amgen, Dr. Lydon was the founder, CEO and president of Kinetix, Inc., a biotech company focused on the development of selective protein kinase inhibitors. 

About AnaptysBio
Founded in 2005, AnaptysBio, Inc. is a privately-held company focused on the generation of antibody therapeutics, and the leader in the use of somatic hypermutation (SHM) for antibody discovery and optimization. SHM is the body's natural process for generating potent antibodies.  AnaptysBio's proprietary SHM-XEL platform, which couples fully human antibody libraries with in vitro somatic hypermutation (SHM) in mammalian cells to generate high affinity lead candidates, replicates key features of the human immune system and overcomes limitations of prior antibody technologies.  By harnessing the natural mechanism of antibody maturation under controlled conditions, SHM-XEL allows for the selection of optimal antibody properties such as high affinity, functionality, cross-reactivity and epitope diversity.   AnaptysBio has established broad intellectual property around the use of SHM and is currently building a pipeline of novel therapeutic antibody product candidates. Major investors in AnaptysBio include founding investor Avalon Ventures, as well as Alloy Ventures, Frazier Healthcare Ventures, and Novo A/S. For more information, visit www.anaptysbio.com.

Contacts:

Julie Rathbun
Rathbun Communications
julie@rathbuncomm.com 
206-769-9219

 


'/>"/>
SOURCE AnaptysBio, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology news :

1. David Salt is worth his salt, says Science magazine
2. Protein folding researcher David Baker to receive Sackler Prize in Biophysics
3. David Rose to present Howe School lecture on new technologies and business models, Jan. 29
4. American Society for Microbiology honors David Masopust for research on T cell memory
5. U of As David Schindler confirms untold levels of oil sands pollution on the Athabasca
6. Leader in genetics, Dr. David L. Rimoin, receives ACMG Foundation Lifetime Achievement Award
7. UMCES fisheries biologist Dr. David Secor receives USM Regents Faculty Award for research
8. Filmmakers Joel and Ethan Coen among 2011 Dan David Prize winners
9. David and Goliath viruses shed light on the origin of jumping genes: UBC study
10. Biochemist David Deamer explores how life began in new book, First Life
11. BIDMC scientist David J. Friedman, M.D., receives award from Doris Duke Charitable Foundation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/29/2017)... 2017  higi, the health IT company that operates ... America , today announced a Series B investment ... EveryMove. The new investment and acquisition accelerates higi,s strategy ... transform population health activities through the collection and workflow ... higi collects and secures data today on behalf of ...
(Date:3/24/2017)... Mar 24, 2017 Research and Markets has ... Market Analysis & Trends - Industry Forecast to 2025" report ... ... at a CAGR of around 15.1% over the next decade to ... report analyzes the market estimates and forecasts for all the given ...
Breaking Biology News(10 mins):
(Date:4/21/2017)... ... April 21, 2017 , ... The University of Connecticut, ... funding to three startups through the UConn Innovation Fund. The $1.5 million UConn ... affiliated with UConn. , The UConn Innovation Fund provides investments of up to ...
(Date:4/21/2017)... ... April 21, 2017 , ... ... nourishing a range of emerging technology-based businesses, recently earned a $77,518 grant from ... , Founded in 2004, FITCI is Frederick’s first incubator. A non-profit corporation, ...
(Date:4/20/2017)... ... April 20, 2017 , ... USDM Life Sciences , the ... and healthcare industries, is pleased to announce Holger Braemer as Vice President ... Europe GmbH” based in Germany. , Braemer is an integral part of USDM’s ...
(Date:4/20/2017)... ... April 20, 2017 , ... Energetiq ... applications, announced today that Chief Executive Officer (CEO) Debbie Gustafson has been appointed ... the global industry association connecting the electronics manufacturing supply chain. The mission of ...
Breaking Biology Technology: